Jste zde


Genetics Policy Institute

Říjen 2013
Bernard Siegel, JD
Bernie Siegel

Bernard Siegel, JD, founder

The Genetics Policy Institute (GPI) is a leading promoter and defender of stem cell research and other cutting-edge medical research targeting cures. We are the catalyst and provide leadership to the Pro-Cures Movement, an influential global network of stakeholders - from patient-advocacy to science and industry.

GPI pursues this mission through co-sponsorship and management of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, advocating, organizing events, speaking engagements, teaching initiatives, and strategic collaborations. We create positive public awareness for stem cell research and regenerative medicine.

GPI maintains science and legal advisory boards comprised of leading stem cell researchers, disease experts, ethicists and legal experts as well as a dedicated fulltime staff of policy, business, science and communication experts that are available to educate the public and media on stem cell issues. GPI serves as the foremost channel of knowledge between the world leading stem cell experts, patient advocates and those who make policy for the general public.

The World Stem Cell Summit, produced by the Genetics Policy Institute (GPI), is the largest interdisciplinary networking meeting of stem cell stakeholders that unites the diverse regenerative medicine community. With the overarching purpose of fostering biomedical research and investments targeting cures, the Summit is the top conference charting the future of this burgeoning field.

The program of the World Stem Cell Summit provides the research, industry, economic and societal context for understanding how all of the pieces of the stem cell puzzle fit together. The agenda features more than 150 speakers and 50 hours of in-depth presentations. Supported by 200 sponsors, exhibitors, endorsing organizations and media partners, the Summit is a three-day showcase of innovation, insight and inspiration.

The Summit's industry track, standing alone, is the largest stem cell business conference in North America with top leaders from cell therapy, biotechnology, tool, devices and pharma in attendance on a program that covers in-depth the issues pertinent to translating basic research into cures, including discussions on regulatory pathways, cell standardization, reimbursements, financing, venture capital and economic development.


Bernard Siegel is the founder and Executive Director of Genetics Policy Institute (GPI), a nonprofit organization with offices in Palm Beach, Florida and Palo Alto, California. Mr. Siegel received his undergraduate and law degrees from the University of Miami (BA 1972, JD 1975). He is a member of the Florida Bar since 1975. He first became involved with the scientific community when, in 2002, he filed a landmark legal case seeking a guardian for an alleged human clone, a case that was widely credited for exposing the clone as a sham. That experience inspired Mr. Siegel to trade his 30-year courtroom career to found GPI, which leads a global "Pro-Cures Movement".

Mr. Siegel is a frequent speaker and consultant on the subjects of stem cells, public policy, patient advocacy and the societal implications of longevity. Mr. Siegel has served on the governing boards for the Coalition for Advancement of Medical Research (CAMR), Americans for Cures Foundation, and the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine. He has also served on committees for the Alliance for Regenerative Medicine (ARM) and the International Society for Stem Cell Research (ISSCR). He serves on Advisory Panels for the New England Regional Spinal Cord Injury Center at Boston medical Center and Sabrina Cohen Foundation for Stem Cell Research. He is a member of the American Society for Bioethics + Humanities and the International Society for Cell Therapy (ISCT).